Details of the Drug

General Information of Drug (ID: DMBG0N4)

Drug Name
Cibenzoline
Synonyms
Cibenzolina; Cibenzolina [INN-Spanish]; Cibenzoline; Cibenzoline (INN); Cibenzoline [INN]; Cibenzolinum; Cibenzolinum [INN-Latin]; Cifenline; Cifenline (USAN); Cifenline [USAN]; Ro 22-7796; Ro 227796; UP 33901; (+-)-2-(2,2-Diphenylcyclopropyl)-2-imidazoline; 1H-Imidazole, 2-(2,2-diphenylcyclopropyl)-4,5-dihydro-, (+-)-; 2-(2,2-Diphenyl-cyclopropyl)-4,5-dihydro-1H-imidazole; 2-(2,2-diphenylcyclopropyl)-2-imidazoline; 2-(2,2-diphenylcyclopropyl)-4,5-dihydro-1H-imidazole; 53267-01-9; C18H18N2; CHEMBL87045; EINECS 258-453-7
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 262.3
Logarithm of the Partition Coefficient (xlogp) 2.7
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
Bioavailability
86% of drug becomes completely available to its intended biological destination(s) [1]
Clearance
The drug present in the plasma can be removed from the body at the rate of 8.6 mL/min/kg [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 7.3 hours [2]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 24.77535 micromolar/kg/day [3]
Unbound Fraction
The unbound fraction of drug in plasma is 0.5% [2]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 4.1 L/kg [2]
Chemical Identifiers
Formula
C18H18N2
IUPAC Name
2-(2,2-diphenylcyclopropyl)-4,5-dihydro-1H-imidazole
Canonical SMILES
C1CN=C(N1)C2CC2(C3=CC=CC=C3)C4=CC=CC=C4
InChI
IPOBOOXFSRWSHL-UHFFFAOYSA-N
InChIKey
1S/C18H18N2/c1-3-7-14(8-4-1)18(15-9-5-2-6-10-15)13-16(18)17-19-11-12-20-17/h1-10,16H,11-13H2,(H,19,20)
Cross-matching ID
PubChem CID
2747
ChEBI ID
CHEBI:135083
CAS Number
53267-01-9
DrugBank ID
DB13358
INTEDE ID
DR0318

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [4]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Gene/Protein Processing [5]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Gene/Protein Processing [5]
Eukaryotic translation initiation factor 2A (EIF2A) OTWXELQP EIF2A_HUMAN Post-Translational Modifications [5]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Gene/Protein Processing [6]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Protein Interaction/Cellular Processes [5]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Gene/Protein Processing [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4 Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A. Drug Metab Dispos. 2000 Sep;28(9):1128-34.
5 Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation. Neuro Oncol. 2011 Mar;13(3):267-79. doi: 10.1093/neuonc/noq195. Epub 2011 Feb 3.
6 Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.